Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Current Assets (2017 - 2025)

Serina Therapeutics' Current Assets history spans 9 years, with the latest figure at $11.5 million for Q3 2025.

  • For Q3 2025, Current Assets rose 112.0% year-over-year to $11.5 million; the TTM value through Sep 2025 reached $11.5 million, up 112.0%, while the annual FY2024 figure was $5.7 million, 25.5% down from the prior year.
  • Current Assets for Q3 2025 was $11.5 million at Serina Therapeutics, up from $8.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $11.5 million in Q3 2025 and bottomed at $1.2 million in Q3 2022.
  • The 5-year median for Current Assets is $2.3 million (2021), against an average of $4.4 million.
  • The largest annual shift saw Current Assets soared 560.52% in 2024 before it tumbled 35.62% in 2025.
  • A 5-year view of Current Assets shows it stood at $2.2 million in 2021, then grew by 9.8% to $2.5 million in 2022, then soared by 210.6% to $7.6 million in 2023, then decreased by 25.5% to $5.7 million in 2024, then surged by 102.55% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Current Assets are $11.5 million (Q3 2025), $8.0 million (Q2 2025), and $5.8 million (Q1 2025).